JOURNAL ARTICLE
RESEARCH SUPPORT, NON-U.S. GOV'T
Add like
Add dislike
Add to saved papers

Effect of botulinum toxin on pressure pain threshold and EMG power spectrum of masseter muscle during sustained fatiguing contraction.

OBJECTIVES: The aims of this study were to test the effect of botulinum toxin on a reversible, prolonged, experimental pain and on muscle fatigue in human masseter muscle, both caused by a sustained clench.

DESIGN: The masseter muscles were injected with botulinum toxin in 19 subjects and with isotonic saline in 16 subjects. We measured electromyographic activity at maximum voluntary contraction, pressure pain threshold before and after a 70% maximum voluntary contraction clench sustained to pain tolerance, and the median frequency of the electromyographic power spectrum during that clench at baseline and at 1, 2, and 3 mos after botulinum toxin or saline injection.

RESULTS: After botulinum toxin injection, the botulinum toxin group had a reduced maximum voluntary contraction for the ensuing 3 mos and smaller decreases in pressure pain threshold from before to after the sustained clench. Also, the change in median frequency from before to after the sustained clench did not significantly differ during the postinjection sessions. However, postinjection, preclench median frequency was lower in the group injected with botulinum toxin.

CONCLUSIONS: We interpret the reduced change in pressure pain threshold with botulinum toxin as a clinically modest but statistically significant analgesic effect on this model of acute muscle pain.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app